Prednisolone-Darnitsa
Release form:
Release form:
Intramuscular, intravenous administration: systemic connective tissue diseases: systemic lupus erythaematosus, dermatomyositis, scleroderma, polyarteritis nodosa, ankylosing spondylitis; haematological diseases: acute haemolytic anaemia, lymphogranulomatosis, granulocytopenia, thrombocytopenic purpura, agranulocytosis, different forms of leukemia; skin diseases: common eczema, erythema multiforme, pemphigus vulgaris, erythroderma, exfoliative dermatitis, seborrheic dermatitis, psoriasis, alopecia, adrenogenital syndrome; replacement therapy: Addisonian crisis; emergency conditions: severe forms of nonspecific ulcerative colitis and Crohn's disease, shock (burn, traumatic, surgical, anaphylactic, toxic, blood transfusion shock), acute severe asthma, acute adrenal insufficiency, hepatic coma, severe allergic and anaphylactic reactions, hypoglycema. Intraarticular administration: chronic polyarthritis, osteoarthritis of large joints, rheumatoid arthritis, post-traumatic arthritis, arthrosis.